Angiotensin I/II (1-5) Protocol Guide

Angiotensin I/II (1-5), SKU A1047, is a pentapeptide composed of Asp-Arg-Val-Tyr-Ile. The product dossier describes this fragment as derived from angiotensin I and angiotensin II and associated with the renin-angiotensin system, including blood pressure regulation and aldosterone release stimulation. Because no directly matched paper evidence is available for this product entry, the guidance below focuses on the stated dossier properties, controlled sample preparation, and basic assay quality practices rather than claiming a validated dose, potency, receptor profile, or disease-specific outcome.

The Angiotensin I/II (1-5) product page identifies the material as a solid compound with a molecular weight of 664.75 Da and formula C30H48N8O9. It is described as insoluble in water but soluble in DMSO and ethanol. These solvent constraints are central to experimental design: aqueous assay systems require a controlled stock preparation and a vehicle-matched dilution workflow.

What This Product Solves

This reagent solves a practical standardization problem in renin-angiotensin system research: investigators can introduce a chemically defined Asp-Arg-Val-Tyr-Ile peptide fragment instead of relying on variable endogenous peptide generation during an experiment. That makes it suitable for workflows examining a blood pressure regulation peptide, vascular responses, renal handling, or aldosterone release stimulation when the experimental question specifically concerns this fragment.

For hypertension research, the reagent can be used as a defined test input in cellular, tissue, or biochemical assays that have already established appropriate biological readouts. The product dossier describes vasoconstrictor activity and a contribution to increased blood pressure, but those statements should be treated as product-context information rather than as a substitute for assay-specific validation. A no-paper mode workflow should therefore begin with a pilot that confirms solubility, vehicle tolerance, sample integrity, and measurable assay response before larger studies are attempted.

This material is not intended to resolve questions about every angiotensin metabolite or every component of peptide hormone vasoconstriction. It should not automatically replace angiotensin 1, angiotensin II, or other pathway reagents in experiments that require a parent peptide, a different cleavage product, or a receptor-selective comparison.

Protocol Parameters

• Assay: Molecular identity and mass calculation | Value: 664.75 Da; formula C30H48N8O9 | Applicability: Stock preparation, molar conversion, and identity records | Rationale: Use the stated molecular weight when converting a weighed amount to molar quantity, and retain the formula and SKU in the experiment record to prevent substitution with another angiotensin fragment | Evidence basis: Product dossier
• Assay: DMSO stock preparation | Value: Solubility ≥66.5 mg/mL | Applicability: Preparation of a concentrated organic-solvent stock before aqueous dilution | Rationale: DMSO is a dossier-supported solvent for this compound; confirm that the final assay vehicle is tolerated by the biological system and remains matched across treatment groups | Evidence basis: Product dossier
• Assay: Ethanol stock preparation | Value: Solubility ≥69.5 mg/mL | Applicability: Alternative stock preparation when ethanol is compatible with the assay | Rationale: Ethanol is also listed as a compatible solvent, but the selected vehicle should be determined by assay tolerance, evaporation control, and downstream measurement requirements | Evidence basis: Product dossier
• Assay: Storage of solid material | Value: −20 °C | Applicability: Unopened material and appropriately handled solid aliquots | Rationale: Maintain the stated storage temperature and minimize unnecessary exposure to ambient humidity, heat, and repeated handling | Evidence basis: Product dossier
• Assay: Working concentration and biological dose | Value: Not specified in the product dossier | Applicability: Cell, tissue, biochemical, or animal study design | Rationale: Establish the concentration range empirically with a pilot and suitable controls; do not infer a universal effective concentration from the product description | Evidence basis: Product-dossier limitation

Workflow Setup and QC Checklist

Before opening the vial

• Record SKU A1047, lot information, receipt condition, storage history, and the intended assay system.
• Confirm that the experiment requires the Asp-Arg-Val-Tyr-Ile fragment rather than a parent angiotensin peptide or another metabolite.
• Plan the solvent control before making the stock. Every treated sample should have a matched vehicle condition containing the same solvent exposure without peptide.

Stock preparation

Allow the container to equilibrate in a dry environment before opening so that condensation is minimized. Inspect the solid for unexpected discoloration, visible contamination, or material loss and document any observation. Use the stated molecular weight for the mass-to-mole calculation, then dissolve the material in DMSO or ethanol using gradual addition and controlled mixing. Do not add the dry compound directly to an aqueous assay medium and assume that it will dissolve uniformly.

After dissolution, inspect the stock for particles, haze, or undissolved material. If the stock is not visibly uniform, stop and resolve the preparation problem rather than compensating by assuming that the undissolved fraction is biologically available. Use low-binding, solvent-compatible tubes where appropriate, label the solvent and calculated concentration clearly, and prepare small working aliquots to reduce repeated freeze-thaw exposure.

Aqueous dilution and assay controls

Introduce the organic stock into the aqueous assay medium under active mixing and in the same addition order used for every treatment group. Check the final mixture for precipitation immediately after dilution and again after the planned equilibration period. Because the dossier specifies water insolubility, precipitation should be treated as a failed preparation or an unvalidated condition, not as evidence of biological inactivity.

Include an untreated control, a vehicle control, and the biological reference controls required by the selected assay. Record the final solvent percentage, mixing sequence, exposure interval, temperature, and sample appearance. If the study measures a blood pressure regulation peptide response, renal endpoint, vasoconstrictor response, or aldosterone release stimulation, define the primary readout and acceptance criteria before testing unknown samples.

Related workflow resources

Angiotensin I/II (1-5): Technical Use in RAS Research Workflows provides a complementary overview of using this defined fragment in cardiovascular and renal study planning; it does not replace assay-specific validation.

Technical Guidance for Angiotensin I/II (1-5) in RAS Assays complements this article by emphasizing solubility and storage controls for reproducible RAS assay handling.

Common Failure Modes and Fixes

Visible precipitation after dilution

Likely cause: The aqueous phase exceeds the practical solubility of the fragment, the stock was added too quickly, or the vehicle was not mixed adequately. Fix: Recheck the stock preparation, use a compatible solvent control, optimize the addition sequence, and verify clarity after dilution. Do not interpret a precipitated preparation as a valid exposure.

Variable results between treatment groups

Likely cause: Unequal vehicle content, inconsistent mixing, adsorption to unsuitable plasticware, or differences in working-stock age. Fix: Prepare treatment and vehicle solutions using the same workflow, use consistent tube materials, mix each solution in a controlled manner, and document aliquot use and handling history.

No measurable biological response

Likely cause: The chosen readout may not reflect the fragment's stated pathway context, the concentration may be inappropriate, or the material may not have remained in solution. Fix: First verify identity, calculation, solubility, vehicle tolerance, and assay performance. Then perform a structured pilot rather than increasing the dose without confirming sample integrity.

Confusion with another angiotensin reagent

Likely cause: Similar product names or abbreviated labels can obscure the difference between a pentapeptide and a parent peptide. Fix: Put the full name, sequence, SKU, molecular weight, and solvent on the working record and sample labels. Do not use an angiotensin I/II (1-5) result to make a direct claim about a different angiotensin species.

Scope and Limitations

The most defensible use of this compound is within cardiovascular and renal workflows focused on the renin-angiotensin system, including hypertension research, blood pressure regulation, and aldosterone-related measurements. The product dossier describes the fragment as a vasoconstrictor peptide fragment and links it to sodium retention and aldosterone release, but the dossier does not establish a universal response across species, tissues, cell types, or assay formats.

No directly matched paper evidence is available here to support a recommended dose, exposure duration, receptor-binding value, pharmacokinetic parameter, tissue-specific potency, or comparative efficacy claim. Those variables must be determined within the user's validated model. Similarly, the stated storage temperature should not be expanded into an unsupported stability claim for reconstituted solution. Record preparation date, solvent, appearance, and storage handling for every working aliquot.

Do not extend this reagent to unrelated peptide signaling, off-target screening, or non-RAS studies without independent evidence that the experimental question is appropriate. If the study requires endogenous enzymatic generation, parent-peptide processing, or quantitative metabolite profiling, this defined fragment alone may not reproduce the required biology.

Conclusion

Angiotensin I/II (1-5) is a defined Asp-Arg-Val-Tyr-Ile reagent for controlled renin-angiotensin system research. Its practical advantages are a stated molecular identity, defined DMSO and ethanol solubility, and a specified −20 °C storage condition. Reliable use depends on solvent-matched controls, careful aqueous dilution, visible-solution checks, aliquot discipline, and assay-specific pilot validation. In the absence of directly matched paper evidence, these handling controls and explicit scope boundaries are essential for interpreting results in hypertension, renal, vascular, and aldosterone-related workflows.